What Daiichi Sankyo Company (TSE:4568)'s ENHERTU EMA Filing and AI Oncology Push Mean For Shareholders [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
early-stage HER2 positive breast cancer, a new AI-focused collaboration with BostonGene in antibody drug conjugate development, board-level succession in global R&D leadership, and an amended legal claim filed against the company in Japan. Together, these updates highlight how Daiichi Sankyo is pushing further into oncology innovation and data-driven drug development while managing governance and legal complexity. We'll now examine how EMA's validation of an expanded ENHERTU indication may influence Daiichi Sankyo's existing investment narrative in oncology. The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. Daiichi Sankyo Company Investment Narrative Recap To own Daiichi Sankyo, you need to believe its antibody drug conjugate platform, led by ENHERTU, can keep underpinning growth despite concentration risk in a few oncology products. EMA validation of ENHERTU in early-stage
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Esperion to acquire Corstasis for cardiovascular franchise expansion [Yahoo! Finance]Yahoo! Finance
- Antibody-drug Conjugates (ADCs) in Oncology Market Competitive Landscape Report 2026: Comprehensive Insights About 200+ Companies and 220+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]Yahoo! Finance
- CellCarta Appoints Ehab A. El-Gabry, MD, as Chief Medical Officer & Head of Companion Diagnostics to Advance CDx Strategy, Digital Pathology and AI [Yahoo! Finance]Yahoo! Finance
- Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&DBusiness Wire
- ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast CancerBusiness Wire